985. Deputy Ken O'Flynn asked the Minister for Health whether any maximum reimbursement thresholds, indicative cost bands, or comparative pricing references are used when assessing applications under the Treatment Abroad Scheme. [36583/26]
986. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has identified any jurisdictions with materially higher reimbursement costs under the treatment abroad scheme for equivalent procedures. [36584/26]
987. Deputy Ken O'Flynn asked the Minister for Health the number of medicines currently awaiting a commercial proposal from a marketing authorisation holder following an invitation by the HSE; the duration each application has remained at that stage; and if she will make a statement on the matter. [36586/26]
988. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any internal monitoring system tracking delays attributable to marketing authorisation holders during the pricing and reimbursement process; and if so, to provide details. [36587/26]
989. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been carried out regarding the impact on patient access arising from the absence of statutory or administrative deadlines for the submission of commercial proposals by marketing authorisation holders. [36588/26]
990. Deputy Ken O'Flynn asked the Minister for Health whether consideration has been given to introducing statutory or regulatory timeframes governing engagement by marketing authorisation holders once invited to submit a commercial proposal to the HSE. [36589/26]
991. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE publishes, or intends to publish, anonymised data on delays in the pricing and reimbursement process attributable to marketing authorisation holders. [36590/26]
992. Deputy Ken O'Flynn asked the Minister for Health whether any escalation mechanism exists where a pricing and reimbursement application remains inactive for an extended period due to the absence of a commercial proposal from a marketing authorisation holder. [36591/26]
993. Deputy Ken O'Flynn asked the Minister for Health whether the absence of formal timelines for commercial engagement by marketing authorisation holders has been identified as a governance, transparency or patient-access risk within the medicines reimbursement system. [36592/26]
994. Deputy Ken O'Flynn asked the Minister for Health whether any comparative review has been carried out examining how other EU jurisdictions manage delays by marketing authorisation holders during medicines pricing and reimbursement negotiations. [36593/26]
995. Deputy Ken O'Flynn asked the Minister for Health the number of minors referred from Ireland to NHS Children and Young Person Gender Services in the United Kingdom in each year from 2020 to date in 2026, broken down by age and sex. [36600/26]
996. Deputy Ken O'Flynn asked the Minister for Health the total expenditure incurred under the treatment abroad scheme in relation to referrals of minors for gender-related assessment or treatment abroad in each year since 2020. [36601/26]
997. Deputy Ken O'Flynn asked the Minister for Health whether any formal written policy, clinical governance framework, or risk assessment governs referrals of minors abroad for gender-related healthcare; and if she will provide details. [36602/26]
998. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has undertaken any independent review of outcomes, safeguarding issues, regret rates, detransition rates, or long-term psychological outcomes associated with referrals of minors abroad for gender-related healthcare.; and if she will make a statement on the matter. [36603/26]
999. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any assessment of the implications of the final Cass Review for Irish clinical practice regarding minors referred abroad for gender-related healthcare. [36604/26]
1000. Deputy Ken O'Flynn asked the Minister for Health whether any pause, restriction, or revised clinical threshold was considered following publication of the Cass Review in relation to referrals of minors abroad for gender-related healthcare. [36605/26]
1001. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has issued updated clinical guidance to GPs, consultant paediatricians, psychiatrists, or CAMHS teams concerning referrals of minors for gender-related healthcare abroad following changes introduced by the NHS in September 2024. [36606/26]
1002. Deputy Ken O'Flynn asked the Minister for Health the number of Irish minors currently awaiting referral, assessment, or treatment through overseas gender-related healthcare pathways supported by the Treatment Abroad Scheme. [36607/26]
1003. Deputy Ken O'Flynn asked the Minister for Health whether any Irish clinicians currently participate in multidisciplinary assessment processes connected to overseas gender-related healthcare referrals for minors. [36608/26]
1004. Deputy Ken O'Flynn asked the Minister for Health whether the updated Irish gender healthcare model of care will include a national audit framework, outcomes monitoring system, detransition support pathway, and safeguarding review mechanism for minors. [36609/26]
1010. Deputy Ken O'Flynn asked the Minister for Health whether the HSE or her Department intends to introduce a formal national obesity-attributable disease modelling framework for Ireland; the proposed timeline for same; and if she will make a statement on the matter. [36641/26]
1011. Deputy Ken O'Flynn asked the Minister for Health whether any national cost-of-illness study is currently underway regarding obesity-related disease expenditure across the health service; and if she will make a statement on the matter. [36642/26]
1012. Deputy Ken O'Flynn asked the Minister for Health whether the HSE centrally measures the proportion of hospital admissions attributable to obesity-related conditions; and if not, whether there are plans to introduce such measurement systems. [36643/26]
1013. Deputy Ken O'Flynn asked the Minister for Health the estimated annual expenditure associated with obesity-related prescribing, including diabetes, cardiovascular and weight-management medications, in each year since 2020. [36644/26]
1014. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been carried out regarding the projected impact of obesity-related disease on future acute hospital capacity demand and workforce requirements to 2035. [36645/26]